Anthracycline

Agendia Presents Data at Miami Breast 2024 Demonstrating MammaPrint® + BluePrint®’s Ability to Further Stratify Tumor Categories in Hormone-Positive Breast Cancer, Highlighting Response to Different Chemotherapy Regimens

Retrieved on: 
Friday, March 8, 2024

The first poster, titled MammaPrint® and BluePrint® predict anthracycline chemosensitivity in patients with HR+HER2-early-stage breast cancer enrolled in FLEX, (Audeh, W., et al.

Key Points: 
  • The first poster, titled MammaPrint® and BluePrint® predict anthracycline chemosensitivity in patients with HR+HER2-early-stage breast cancer enrolled in FLEX, (Audeh, W., et al.
  • ), investigates the associations between MammaPrint and BluePrint classifications, therapy regimen, and the likelihood of achieving a pathologic Complete Response (pCR).
  • The second poster, titled Prediction of chemotherapy benefit by MammaPrint® in patients with HR+HER2-early-stage breast cancer from real-world evidence studies (Audeh, W., et al.
  • Taken together, these findings indicate the utility of MammaPrint to predict neoadjuvant and adjuvant chemotherapy benefit in this patient population.

Moleculin Announces 2023 Year-End Annamycin Clinical Trials Preliminary Data and 2024 Expectations for Multiple Data Readouts and Transition to Pivotal Phase 2B/3

Retrieved on: 
Wednesday, January 24, 2024

"Over the course of 2023, we delivered on our promise for a year of important data from our Annamycin clinical development programs.

Key Points: 
  • "Over the course of 2023, we delivered on our promise for a year of important data from our Annamycin clinical development programs.
  • We are well-positioned to continue building upon our encouraging growing body of preliminary clinical data and transition to pivotal Phase 2B/3 clinical trials by year-end 2024.
  • With our recent financing in December 2023, we have extended our runway into the fourth quarter of 2024, as well.
  • WP1122 successfully completed a Phase 1 clinical trial, which established a recommended safe dose for future potential Phase 1B or Phase 2 clinical trials.

Kexing Biopharm Introduces Eribulin Mesylate Injection, Expanding Its Overseas Product Portfolio

Retrieved on: 
Friday, January 5, 2024

This is the fifth major breast cancer medication introduced by Kexing Biopharm, which further enriches its product portfolio for breast cancer treatment.

Key Points: 
  • This is the fifth major breast cancer medication introduced by Kexing Biopharm, which further enriches its product portfolio for breast cancer treatment.
  • Eribulin Mesylate Injection is the fifth breast cancer medication of Kexing Biopharm.
  • This product can form an effective combination with the existing four ones that have been introduced by Kexing Biopharm and are in the process of obtaining overseas registrations.
  • This collaboration provides Kexing Biopharm with exclusive commercialization licensing for Eribulin Mesylate Injection from Xiling Lab Co., Ltd. in 36 countries, including Brazil, Argentina, Singapore, Thailand, Egypt, South Africa, India, and Saudi Arabia and so on.

Human medicines European public assessment report (EPAR): Vegzelma, bevacizumab, Date of authorisation: 17/08/2022, Revision: 5, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024

Human medicines European public assessment report (EPAR): Vegzelma, bevacizumab, Date of authorisation: 17/08/2022, Revision: 5, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Vegzelma, bevacizumab, Date of authorisation: 17/08/2022, Revision: 5, Status: Authorised

Global Acute Myeloid Leukemia (AML) Treatment Market Trends and Forecasts, 2020-2022 & 2023-2028 with Profiles of Major Players - AbbVie, Daiichi Sankyo, GlaxoSmithKline, Pfizer and Servier - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 24, 2023

The "Global Acute Myeloid Leukemia (AML) Treatment Market: Forecast and Trends" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Acute Myeloid Leukemia (AML) Treatment Market: Forecast and Trends" report has been added to ResearchAndMarkets.com's offering.
  • The global AML treatment market was valued at nearly $3.5 billion in 2022.
  • This study's primary objective is to conduct a comprehensive analysis of the AML treatment market, offering insights into its dynamics, prevailing trends, and the overall market landscape.
  • Technological advancements in the field of blood cancer have played a pivotal role in propelling the AML treatment market forward.

Moleculin Doses First Subjects in Phase 2 Portion of Clinical Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML)

Retrieved on: 
Monday, October 2, 2023

HOUSTON, Oct. 2, 2023 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat cancers and viruses, today announced the initial subjects have been treated in the Phase 2 portion of the Company's Phase 1B/2 trial evaluating Annamycin in combination with Cytarabine (Ara-C) for the treatment of subjects with AML (MB-106).

Key Points: 
  • Walter Klemp, Chairman and Chief Executive Officer of Moleculin commented, "This milestone marks an important step in advancing the development of Annamycin for the treatment of AML.
  • Based on the positive preliminary results demonstrated in the Phase 1B portion of this trial, we continue to believe that Annamycin has the potential to be a meaningful treatment option for the treatment of AML.
  • As previously announced, Moleculin successfully and safely completed the Phase 1B portion of the trial at 230 mg/m2 of Annamycin in this combination study in August 2023.
  • For more information about the MB-106 Phase 1/2 trial, visit clinicaltrialsregister.eu and reference EudraCT 2020-005493-10 or clinicaltrials.gov and reference NCT05319587.

Clinigen divests global rights to four cancer support therapies to CNX Therapeutics

Retrieved on: 
Thursday, August 10, 2023

Clinigen Limited (‘Clinigen’), the global pharmaceutical services company, has completed the divestment of four cancer supportive care products from its established brands portfolio to CNX Therapeutics, a speciality pharmaceutical company with a focus on improving access to medicines that are critical to the well-being of patients.

Key Points: 
  • Clinigen Limited (‘Clinigen’), the global pharmaceutical services company, has completed the divestment of four cancer supportive care products from its established brands portfolio to CNX Therapeutics, a speciality pharmaceutical company with a focus on improving access to medicines that are critical to the well-being of patients.
  • Cardioxane®, used in adults with advanced or metastatic breast cancer to prevent long-term harmful effects on the heart caused by treatment with certain anthracyclines.
  • Savene®, used to treat anthracycline extravasation in adults, a rare condition that can impact cancer patients.
  • Totect®, used for the treatment of anthracycline extravasation as well as for preventing cardiomyopathy associated with doxorubicin in women with metastatic breast cancer.

Global Doxorubicin Market Report 2023: Growing Demand for Effective Cancer Treatments Fuels the Sector - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 8, 2023

The "Global Doxorubicin Market Report and Forecast 2023-2031" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Doxorubicin Market Report and Forecast 2023-2031" report has been added to ResearchAndMarkets.com's offering.
  • The global doxorubicin market size attained a value of USD 1218 million in 2022.
  • [Doxorubicin is used primarily in the treatment of a wide range of cancers, including breast cancer, ovarian cancer, lung cancer, stomach cancer, thyroid cancer, bladder cancer, multiple myeloma, Hodgkin's lymphoma, and non-Hodgkin's lymphomas.
  • The global market for doxorubicin is expected to continue to grow in the coming years, driven by an increasing incidence of cancer and a growing demand for effective treatments.

OLON Enters in ADC Market

Retrieved on: 
Tuesday, May 30, 2023

The ultra-high-containment production line will produce high-potency and toxic products and will therefore reach containment level OEB6 (target OEL 10 ng/m3).

Key Points: 
  • The ultra-high-containment production line will produce high-potency and toxic products and will therefore reach containment level OEB6 (target OEL 10 ng/m3).
  • This complete, closed-loop system will include all steps of the process: synthesis, isolation, drying and analysis: an ultra-high-containment plant.
  • Olon is one of few suppliers in the global API market able to integrate every level of containment from the initial API development to commercial manufacturing and from a few grams to hundreds of kilograms.
  • Olon has a global network of 11 manufacturing sites and 7 R&D centers across the globe.

Junshi Biosciences Announces Acceptance of the Supplemental NDA for Toripalimab in Combination with Chemotherapy for Advanced Triple-negative Breast Cancer

Retrieved on: 
Tuesday, May 23, 2023

Unfortunately, advanced TNBC does not respond well to targeted therapy and endocrine therapy, and there are currently no specific treatment methods available.

Key Points: 
  • Unfortunately, advanced TNBC does not respond well to targeted therapy and endocrine therapy, and there are currently no specific treatment methods available.
  • In recent years, clinical studies have shown that immunotherapy in combination with chemotherapy for the treatment of advanced TNBC can achieve better efficacy and tolerability.
  • To this day, however, no immunotherapy drugs have been approved for advanced TNBC in China, and chemotherapy remains the primary treatment option.
  • I am delighted to see the acceptance of the NDA for toripalimab in combination with chemotherapy for the treatment of advanced TNBC.